PK, PD, Safety and Tolerability of Lipegfilgrastim in Healthy Japanese and Caucasian Participants

Pharmacokinetics Clinical Trial

Official title:

A Randomized, Double-Blind Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Single Subcutaneous Administration of Lipegfilgrastim (Doses up to 100 μg/kg) in Healthy Japanese and Caucasian Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02306915
• Other study ID #: XM22-PK-10036
• Status: Completed
• Phase: Phase 1
• Start date: October 2014
• Est. completion date: May 2015

Study information

• Verified date: November 2021
• Source: Teva Branded Pharmaceutical Products R&D, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Cohorts of Japanese participants will be enrolled and treated prior to cohorts of Caucasian participants for the sake of matching. Every effort will be made to match Caucasian and Japanese participants on a cohort basis at enrollment. Reasonable effort will be made to maintain balance between male and female participants within the cohorts. There will be no replacement of participants following randomization.

Description:

Eligible participants will be admitted to the investigational center and after confirming their eligibility will be randomized to receive a single dose of 30, 60, or 100 μg/kg lipegfilgrastim. There will be 11 visits to the investigational center during the study, including a screening visit, 1 inpatient period (through Day 4 post-dose) and 9 ambulatory visits.

Blood samples for PK, PD and immunogenicity analysis will be collected pre-dose and at specified time points post-dose. A mandatory blood sample for pharmacogenetics (PGx) will be collected from all participants. During the study the following safety assessments will be performed: vital signs measurements,physical examinations, record of adverse events, clinical laboratory tests, urinalysis, safety ECG recordings, local tolerability (injection site reactions), overall tolerability, pregnancy testing, spleen sonography, and concomitant medications

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: May 2015
• Est. primary completion date: March 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 45 Years

Eligibility

Inclusion Criteria:

• Body mass index (BMI) =18.0 and =25 kg/m2.

• Body weight must be = 50 kg and = 90 kg.

• Is in good general health as determined by medical history, physical examination, 12-lead electrocardiography (ECG), vital signs and clinical laboratory tests.

• Subjects are able to read, write and understand English or Japanese; they must be able to understand the requirements of the study and be willing to comply with all trial requirements.

• Female subjects of childbearing potential must have a negative serum ß-human chorionic gonadotropin (ß-hCG) test at screening and negative urine pregnancy test at check-in. All subjects must be either surgically sterile (for females that means documented complete hysterectomy, bilateral oophorectomyor bi-tubal ligations; partial hysterectomy is not sufficient), abstinent throughout the study or, if of reproductive capacity and not abstinent, exercising any 2 different forms of highly effective contraception methods with his/her partner during the entire study period.

o Additional inclusion criteria for Japanese subjects:

• Subject must be a non-naturalized Japanese citizen and hold a Japanese passport.

• Subject must have/had 2 Japanese parents and 4 Japanese grandparents who are all non-naturalized Japanese citizens, as confirmed by interview.

• Subject has been living outside of Japan for 10 years or fewer as confirmed by interview.

o Additional inclusion criterion for Caucasian subjects:

• The subject is Caucasian, and confirms by interview that his/her parents and grandparents are Caucasian and none are of Black/African descent, Middle-Eastern descent or Asian descent.

• -other criteria apply, please contact the investigator for more information

Exclusion Criteria:

• History of hypersensitivity to pegfilgrastim, filgrastim, lenograstim, Escherichia coli derived proteins, or to any excipients (glacial acetic acid, sodium hydroxide, sorbitol, polysorbate 20).

• Prior exposure to filgrastim, pegfilgrastim or lenograstim or other granulocyte colony stimulating factors (G-CSFs) in clinical development less than 6 months before randomization.

• Findings of splenomegaly on sonography, defined by splenic length in excess of 12.3 cm (Andrews, 2000; Benter et al, 2011) and clinical judgment.

• Existence or recent history of persistent pulmonary infiltrates or recent pneumonia, or current symptoms of upper respiratory infection. In the case of pneumonia, subject may be screened 12 weeks following cessation of antibiotic treatment.

• -other criteria apply, please contact the investigator for more information

Related Conditions & MeSH terms

• Pharmacodynamics
• Pharmacokinetics

Intervention

Drug:
• lipegfilgrastim
lipegfilgrastim 30 µg/kg, 60 µg/kg, 100 µg/kg

Locations

Country	Name	City	State
United Kingdom	Teva Investigational Site 34193	London

Sponsors (1)

Lead Sponsor	Collaborator
Merckle GmbH

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PK: Area under the serum concentration-time curve (AUC), from time 0 to the last measurable concentration (AUC0-t)	2 hours for visits 3, 9; 1 day for visit 10	Days 1-8, 10, 14, 17, 21
Primary	AUC from time 0 extrapolated to infinity (AUC0-8)		Days 1-8, 10, 14, 17, 21
Primary	Maximum observed serum drug concentration (Cmax)		Days 1-8, 10, 14, 17, 21
Primary	Time to maximum observed serum drug concentration (tmax)		Days 1-8, 10, 14, 17, 21
Primary	The percentage of the extrapolated area to infinity in relation to the total area under the curve (%AUCext)		Visits 3, 9, 10
Primary	Apparent serum terminal elimination rate constant (?z)	2 hours for visits 3, 9; 1 day for visit 10	Days 1-8, 10, 14, 17, 21
Primary	Associated elimination half-life (t½)		Days 1-8, 10, 14, 17, 21
Primary	Mean residence time (MRT)		Days 1-8, 10, 14, 17, 21
Primary	Apparent total body clearance (CL/F)		Days 1-8, 10, 14, 17, 21
Primary	Apparent volume of distribution during the terminal phase (Vz/F)		Days 1-8, 10, 14, 17, 21
Primary	PD: ANC area over baseline effect curve (ANC AOBEC)		Days 1-8, 10, 14, 17, 21
Primary	Maximum measured ANC value after dosing (ANC Cmax)		Days 1-8, 10, 14, 17, 21
Primary	Time point at which ANC Cmax is observed (ANC tmax)		Days 1-8, 10, 14, 17, 21
Primary	Time (days) until ANC returns to baseline value		Days 1-8, 10, 14, 17, 21
Primary	CD34+ area over the baseline effect curve (CD34+ AOBEC)		Days 1-8, 10, 14, 17, 21
Primary	Maximum measured CD34+ value after dosing (CD34+ Cmax)		Days 1-8, 10, 14, 17, 21
Primary	Time point at which CD34+ Cmax is observed (CD34+ tmax)		Days 1-8, 10, 14, 17, 21
Secondary	Percentage of Participants with Adverse Events		28 Days